Similar articles for PMID: 17909256

Year	Number of Results
1993	2
1998	1
2000	1
2001	4
2002	6
2003	4
2004	5
2005	16
2006	22
2007	28
2008	17
2009	5
2010	1
2011	1
2012	2
2013	5
2014	3
2015	2
2016	2
2017	4
2018	1
2019	1
2020	1
2021	3
2022	1
2024	0

1

18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?

Weber WA. Weber WA. J Nucl Med. 2007 Oct;48(10):1580-2. doi: 10.2967/jnumed.107.042911. J Nucl Med. 2007. PMID: 17909256 Free article. No abstract available.

2

The role of FDG PET in the management of lymphoma: what is the evidence base?

Kirby AM, Mikhaeel NG. Kirby AM, et al. Nucl Med Commun. 2007 May;28(5):335-54. doi: 10.1097/MNM.0b013e3280895e23. Nucl Med Commun. 2007. PMID: 17414883 Review.

3

18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?

Juweid ME. Juweid ME. J Nucl Med. 2008 Jan;49(1):9-12. doi: 10.2967/jnumed.107.046292. Epub 2007 Dec 12. J Nucl Med. 2008. PMID: 18077522 Free article. Review. No abstract available.

4

PET evaluation of lung cancer.

Bunyaviroch T, Coleman RE. Bunyaviroch T, et al. J Nucl Med. 2006 Mar;47(3):451-69. J Nucl Med. 2006. PMID: 16513615 Free article. Review. No abstract available.

5

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.

Spaepen K, Mortelmans L. Spaepen K, et al. Q J Nucl Med. 2001 Sep;45(3):269-73. Q J Nucl Med. 2001. PMID: 11788819 Review.

6

The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.

Chiusolo P, Sica S, Leone G. Chiusolo P, et al. Hematology. 2003 Dec;8(6):403-8. doi: 10.1080/1024533032000158841. Hematology. 2003. PMID: 14668036

7

FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies.

Basu S, Alavi A. Basu S, et al. Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):427-8. doi: 10.1007/s00259-006-0313-1. Epub 2006 Dec 29. Eur J Nucl Med Mol Imaging. 2007. PMID: 17195072 No abstract available.

8

Positron emission tomography and bone metastases.

Fogelman I, Cook G, Israel O, Van der Wall H. Fogelman I, et al. Semin Nucl Med. 2005 Apr;35(2):135-42. doi: 10.1053/j.semnuclmed.2004.11.005. Semin Nucl Med. 2005. PMID: 15765376 Review.

9

FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.

Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G. Pelosi E, et al. Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16. Q J Nucl Med Mol Imaging. 2008. PMID: 18235420 Free article.

10

Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma.

Guermazi A, Juweid ME. Guermazi A, et al. Br J Radiol. 2006 May;79(941):365-7. doi: 10.1259/bjr/31368041. Br J Radiol. 2006. PMID: 16632614 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

126 results

Results by year